Drugs like Ozempic (GLP-1 agonists) show promise for addiction treatment because they may reduce the fundamental 'wanting' of a substance, rather than just helping a person fight cravings. An addicted patient's core desire is often 'not to want,' and these drugs may directly address that by altering the brain's reward and satiety signaling.

Long-term, high-dose GLP-1 use leads to diminishing returns and significant muscle loss. A more effective strategy is using micro-doses in 90-day cycles, paired with nutritional coaching. This approach uses the drug as a temporary tool to eliminate carb cravings and establish lasting dietary habits.

Beyond direct physiological changes, GLP-1s help correct underlying physiology, which restores the mental and physical resources needed to maintain fundamentals like sleep, exercise, and nutrition. This secondary effect can be more profound than the drug's primary action.

The satiation signal from GLP-1s to the brain stem also down-regulates dopamine and the desire for it. This explains anecdotal reports and active studies on their effect in reducing cravings for nicotine, alcohol, shopping, and gambling.

GLP-1 agonists don't just reduce cravings for food; they suppress wanting and desire in general. Because romantic love operates on the same dopaminergic pathways, these 'anti-desire' drugs may significantly diminish a person's capacity to fall in love or maintain romantic feelings in existing relationships.

As the obesity market matures, the key differentiator may shift from maximum weight loss to tolerability. High discontinuation rates for GLP-1s due to GI side effects create an opportunity for drugs with slightly lower efficacy but a stellar safety profile, which could capture a large and underserved patient segment.

GLP-1 agonists not only reduce hunger but also curb addictive behaviors like gambling. This suggests they impact the brain's fundamental reward systems, which could inadvertently blunt the risk-taking appetite essential for roles like entrepreneurship.

While GLP-1 drugs can jumpstart weight loss by reducing appetite, they don't address poor food quality. If users simply eat less ultra-processed food, they risk severe protein and micronutrient deficiencies, leading to different long-term health consequences.

Aardvark differentiates its drug from GLP-1s by claiming to abrogate hunger (a pain-avoidance drive from fasting), not just diminish appetite (a positive, reward-based drive). This novel mechanism targets the discomfort of food deprivation, offering a distinct approach in the crowded weight-loss market.